Tag: Obesity Treatment
AstraZeneca Advances Oral GLP-1 Elecoglipron to Phase III Programme
AstraZeneca announced positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). The data,...
Lilly’s Obesity Portfolio Wins Full U.S. Insurance Coverage, Reshaping the GLP-1 Landscape
In a pivotal shift for the obesity treatment market, Eli Lilly and Company (NYSE: LLY) has secured formulary coverage across all three of America's...